A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Ontology highlight
ABSTRACT: This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.
DISEASE(S): Adenocarcinoma,Kras G12r,Kras G12s,Nras G12v,Kras G12v,Colorectal Cancer,Nras G12s,Nras G12r,Pancreatic Ductal Adenocarcinoma,Kras G12a,Kras G12c,Kras G13d,Kras G12d,Colon Cancer,Nras G12c,Colorectal Neoplasms,Nras G12d
PROVIDER: 8247 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA